Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Randomized phase II using a one-stage design. Patients are randomized 1:1 to either the monotherapy or combination arms. This requires 42 patients (21 per treatment arm) for each race-based cohort. All the calculations are based on Smart-Design-Indiana at https://iusccc.shinyapps.io/SmartDesign-Indiana/.